SoLAT (Sorafenib Lenvatinib alternating treatment): a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer

In the last decade, several tyrosine kinase inhibitors (TKIs), which disrupt pathways involved in the proliferation and tumorigenesis of thyroid cancer, have been extensively studied. Two different TKIs, lenva...

Source: BMC Cancer - October 4, 2018 Category: Cancer & Oncology Authors: Soo Young Kim, Seok-Mo Kim, Ho-Jin Chang, Bup-Woo Kim, Yong Sang Lee, Cheong Soo Park, Ki Cheong Park and Hang-Seok Chang Tags: Research article Source Type: research